"Despite the setback in the filing date for AMT's lead product GlyberaTM, our Company made substantial progress in 2008 with positive clinical data for GlyberaTM, the development of three new products and the strengthening of our production platform as well as our organization. Because of these important developments we are confident in AMT's future success," said Sander van Deventer, CEO of AMT.
Conference call and webcast presentation
AMT will conduct a conference call open to the public today at 3.00 p.m. CET, which will also be webcast. The dial-in number for the Netherlands is 0800-949-4166 (toll free). The number for Germany is 0800-000-22-63 (toll free). For the UK the number is +44(0)207-107-0611 and for the rest of Europe: +41-91-610-5600. The number for the USA is +1-866-291-4166 (toll free). The webcast can be accessed via AMT's website at http://www.amtbiopharma.com. Please go to the website 15 minutes prior to the call to register, download and install the necessary audio software. Playback of the call will be availably for 24 hours after the call. Dial In: +41-91-612-4330; +44(0)20-7108-6233; or +1-866-416-2558. The archived webcast also will be available for replay shortly after the close of the call.
About Amsterdam Molecular Therapeutics
AMT has a unique gene therapy platform that to date appears to circumvent
many if not all of the obstacles that have prevented gene therapy from
becoming a mainstay of clinical medicine. Using adeno-associated viral (AAV)
vectors as the delivery vehicle of choice for therapeutic genes, the company
has been able to design and validate what is probably the first stable and
scalable AAV production platform. As such, AMT's proprietary platform holds
tremendous promise for thousands of rare (orphan) diseases, especially the
|SOURCE Amsterdam Molecular Therapeutics B.V|
Copyright©2009 PR Newswire.
All rights reserved